Author's response to reviews Title:Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one cisplatin-based systemic therapy in clinical practice Authors:
نویسندگان
چکیده
Daniel Castellano ([email protected]) Javier Puente ([email protected]) Guillermo De Velasco ([email protected]) Isabel Chirivella ([email protected]) Pilar López-Criado ([email protected]) Nicolás Mohedano ([email protected]) Ovidio Fernández ([email protected]) Icíar García-Carbonero ([email protected]) M. Belén González ([email protected]) Enrique Grande ([email protected])
منابع مشابه
From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples
BACKGROUND The efficacy of Vinflunine, after failure of platinum-based chemotherapy in patients with metastatic or recurrent Transitional Cell Cancer of the Urothelial Tract, TCCU, has been demonstrated in an international, randomized, phase III trial comparing Vinflunine plus Best Supportive Care, BSC, with BSC alone. On the basis of that study vinflunine has been approved by the European Medi...
متن کاملCritical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and the United States. For locally advanced or metastatic disease, there are two standard firstline chemotherapy regimens: MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) and gemcitabine/cisplatin. For refractory disease, there is currently no standard treatment. Vinflunine, a second-generation Vinca alka...
متن کاملVinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy
Background A systematic review and meta-analysis of the use of systemic vinflunine (VIN) in the treatment of urothelial carcinoma (UC) was performed to evaluate its efficacy based on current available clinical data. Methods This review was prospectively registered at the International Prospective Register of Systematic Reviews, PROSPERO (registration CRD42016049294). Electronic databases incl...
متن کاملSalvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?
CURRENT SYSTEMIC THERAPY FOR ADVANCED UROTHELIAL CARCINOMA First-line cisplatin-based combination chemotherapy yields a median overall survival (OS) of 12–15months in advanced urothelial carcinoma (UC) and is associated with durable survival in a fraction of patients with excellent performance status and no visceral disease.There are currently no agents approved by the U.S. Food and Drug Admini...
متن کاملVinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
In 2009, vinflunine was introduced as a second-line treatment to be used after the failure of platinum therapy in patients with metastatic urothelial carcinoma (mUC). The present study investigated the administered vinflunine to patients with mUC in standard clinical practice with the aim of evaluating treatment patterns, response, survival parameters and side-effects. Data were collected retro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013